Back to results
US 2026/0083707 A1Published application
Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
AssigneePurdue Pharma L.P.
InventorsThomas Jorg Mehrling, Marco Herling
Life of this patent
Estimating the term…
Abstract
There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
Claims12
-11. (canceled)
A method of treating T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof, comprising parenterally administering to said patient tinostamustine or a pharmaceutically acceptable salt thereof at a dosage level of from 20 mg/m2 to 150 mg/m2 body surface area of the patient.
Dependencies are inferred from the claim text.